Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02551471




Registration number
NCT02551471
Ethics application status
Date submitted
31/08/2015
Date registered
16/09/2015
Date last updated
9/08/2018

Titles & IDs
Public title
Benchmarking Trial Between France and Australia Comparing Management of Primary Rectal Cancer Beyond TME (Total Mesorectum Excision) and Locally Recurrent Rectal Cancer
Scientific title
Secondary ID [1] 0 0
CHUBX 2014/37
Universal Trial Number (UTN)
Trial acronym
PELVICARE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Observational [Patient Registry]
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Other interventions - Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)
Other interventions - MDT (Multidisciplinary team) meeting observation
Other interventions - Semi-structured exploratory interviews and focus group with MDT health professional attendees

French patients -

Australians patients -


Other interventions: Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)
This experiment will consist of an inter-country reading of patients' pelvic MRIs, "blind" to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries.

Other interventions: MDT (Multidisciplinary team) meeting observation
3 per centre with "real" patient cases and "theoretical" patient cases (blinded pelvic MRI re-reading).

Other interventions: Semi-structured exploratory interviews and focus group with MDT health professional attendees
Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Clinical resection rates in both countries
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Concordance rate of operative decisions between France and Australia
Timepoint [1] 0 0
6 months, 12 months
Secondary outcome [2] 0 0
R0 resection rate
Timepoint [2] 0 0
12 months
Secondary outcome [3] 0 0
Disease Free Survival
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
Overall Survival
Timepoint [4] 0 0
12 months
Secondary outcome [5] 0 0
Post-operative morbidity and mortality rates
Timepoint [5] 0 0
30 days
Secondary outcome [6] 0 0
Quality of life questionnaire
Timepoint [6] 0 0
6 months, 12 months
Secondary outcome [7] 0 0
Stress level score
Timepoint [7] 0 0
6 months, 12 months
Secondary outcome [8] 0 0
Analyses of semi-structured interviews
Timepoint [8] 0 0
12 months

Eligibility
Key inclusion criteria
* Patients operable and/or capable of receiving a radiotherapy and/or a chemotherapy
* Patients in care in the French and Australian centres participating in the study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients suffering from primitive rectal cancer at a stage inferior to T4b
* Patients suffering from primitive locally-advanced metastatic rectal cancer (T4NxM1)
* Patients suffering from recurrence of metastatic rectal cancer
* Patients having been refused a surgical procedure because of one or multiple comorbidities

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2018
Sample size
Target
Accrual to date
Final
165
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Peter Maccallum Cancer centre - Melbourne
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital Sydney - Sydney
Recruitment postcode(s) [1] 0 0
VIC 3002 - Melbourne
Recruitment postcode(s) [2] 0 0
NSW 2050 - Sydney
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Bordeaux
Country [2] 0 0
France
State/province [2] 0 0
Clichy
Country [3] 0 0
France
State/province [3] 0 0
Grenoble
Country [4] 0 0
France
State/province [4] 0 0
Lille
Country [5] 0 0
France
State/province [5] 0 0
Lyon
Country [6] 0 0
France
State/province [6] 0 0
Marseille
Country [7] 0 0
France
State/province [7] 0 0
Montpellier
Country [8] 0 0
France
State/province [8] 0 0
Paris
Country [9] 0 0
France
State/province [9] 0 0
Rouen
Country [10] 0 0
France
State/province [10] 0 0
Toulouse

Funding & Sponsors
Primary sponsor type
Other
Name
University Hospital, Bordeaux
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The incidence of rectal cancers is at 15,000 new cases per year in France of which 10 to 15% are locally advanced (T4bNxM0) at the moment of diagnosis. The rate of invaded resection margins (R1) for these locally advanced and fixed rectal tumours varies from 10 to 20%. The invasion of the resection margins triples the risk of local recurrence. In the absence of surgical treatment, the 5-year survival rate for patients having had pelvic recurrence of rectal cancer is lower than 4% whereas it varies from 35 to 40% in cases of curative resection. The care and management of locally advanced and fixed rectal tumours and pelvic recurrence of rectal cancer constitutes, therefore, in the absence of recommendation, a difficult therapeutic problem with great variability in the methods of care and management around the world. These variations in practice can be explained by structural and organizational differences, as well as cultural dissimilarities. With regards to the organization of its healthcare system, Australia is shown to be a leader as regards the care and management of locally advanced and fixed rectal tumours and pelvic recurrence of rectal cancer.
Trial website
https://clinicaltrials.gov/study/NCT02551471
Trial related presentations / publications
Denost Q, Saillour F, Masya L, Martinaud HM, Guillon S, Kret M, Rullier E, Quintard B, Solomon M. Benchmarking trial between France and Australia comparing management of primary rectal cancer beyond TME and locally recurrent rectal cancer (PelviCare Trial): rationale and design. BMC Cancer. 2016 Apr 4;16:262. doi: 10.1186/s12885-016-2286-1.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02551471